Document:

EX-10.04

 Exhibit 10.04 

ADESTO TECHNOLOGIES CORPORATION 

2015 EMPLOYEE STOCK PURCHASE PLAN 

1. PURPOSE. Adesto Technologies Corporation has adopted this Plan effective as of the date of the IPO. The purpose of this Plan is to
provide eligible employees of the Company and the Participating Corporations with a means of acquiring an equity interest in the Company and to enhance such employees’ sense of participation in the Company’s affairs. Capitalized terms not
defined elsewhere in this Plan are defined in Section 28. 
 2. ESTABLISHMENT OF PLAN. The Company proposes to grant rights to
purchase shares of Common Stock to eligible employees of the Company and its Participating Corporations pursuant to this Plan. The Company intends this Plan to qualify as an “employee stock purchase plan” under Section 423 of the Code
(including any amendments to or replacements of such Section), and this Plan shall be so construed, although the Company makes no undertaking or representation to maintain such qualification. Any term not expressly defined in this Plan but defined
in Section 423 of the Code shall have the definition provided by Section 423 of the Code. In addition, with regard to offers of options to purchase shares of Common Stock under the Plan to employees working for a Subsidiary or an Affiliate
outside the United States, this Plan authorizes the grant of options under a Non-Section 423 Component that is not intended to meet the requirements of Section 423 of the Code provided that, to the extent necessary under Section 423
of the Code, the other terms and conditions of this Plan are met. 
 Subject to Section 14, a total of 150,000 shares of Common Stock
is reserved for issuance under this Plan. Subject to Section 14, no more than 2,250,000 shares of Common Stock may be issued over the term of this Plan. In addition, on each January 1 of each calendar year, the aggregate number of shares
of Common Stock reserved for issuance under the Plan shall be increased automatically by the number of shares equal to one percent (1%) of the total number of outstanding shares of Common Stock outstanding on the immediately preceding
December 31 (rounded down to the nearest whole share); provided, that the Board or the Committee may in its sole discretion reduce the amount of the increase in any particular year. The number of shares initially reserved for issuance
under this Plan and the maximum number of shares that may be issued under this Plan shall be subject to adjustments effected in accordance with Section 14. Any or all such shares may be granted under the Section 423 Component. 

3. ADMINISTRATION. The Plan will be administered by the Committee. Subject to the provisions of this Plan and the limitations of
Section 423 of the Code or any successor provision in the Code, all questions of interpretation or application of this Plan shall be determined by the Committee and its decisions shall be final and binding upon all eligible employees and
Participants. The Committee will have full and exclusive discretionary authority to construe, interpret and apply the terms of this Plan, to determine eligibility, to designate the Participating Corporations, to determine whether Participating
Corporations shall participate in the Section 423 Component or Non-Section 423 Component and to decide upon any and all claims filed under the Plan. Every finding, decision and determination made by the Committee will, to the full extent
permitted by law, be final and binding upon all parties. Notwithstanding any provision to the contrary in this Plan, the Committee may adopt rules, sub-plans, and/or procedures relating to the operation and administration of this Plan designed to
comply with local laws, regulations or customs or to achieve tax, securities law or other objectives for eligible employees outside of the United States. The Committee will have the authority to determine the Fair Market Value of the Common Stock
(which determination shall be final, binding and conclusive for all purposes) in accordance with Section 8 below and to interpret Section 8 of this Plan in connection with circumstances that impact the Fair Market Value. Members of the
Committee shall receive no compensation for their services in connection with the administration of this Plan, other than standard fees as established from time to time by the Board for services rendered by Board members serving on Board committees.
All expenses incurred in connection with the administration of this Plan shall be paid by the Company. For purposes of this Plan, the Committee may designate separate offerings under the Plan (the terms of which

 
need not be identical) in which eligible employees of one or more Participating Corporations will participate, even if the dates of the applicable Offering Periods of each such offering are
identical. 
 4. ELIGIBILITY. 

(a) Any employee of the Company or the Participating Corporations is eligible to participate in an Offering Period under this Plan, except
that one or more of the following categories of employees may be excluded from eligibility under this Plan by the Committee (other than where such exclusion is prohibited by applicable law): 

(i) employees who are customarily employed for twenty (20) hours or less per week; 

(ii) employees who are customarily employed for five (5) months or less in a calendar year; and 

(iii) employees who do not meet any other eligibility requirements that the Committee may choose to impose (within the limits permitted by
the Code). 
 Notwithstanding the foregoing, an individual shall not be eligible if his or her participation in this Plan is prohibited by the law of any
country having jurisdiction over him or her, if complying with the laws of the applicable country would cause the Plan to violate Section 423 of the Code, or if he or she is subject to a collective bargaining agreement that does not provide for
participation in this Plan. 
 (b) No employee who, together with any other person whose stock would be attributed to such employee pursuant
to Section 424(d) of the Code, owns stock or holds options to purchase stock possessing five percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or its Parent or Subsidiary or who, as a
result of being granted an option under this Plan with respect to such Offering Period, would own stock or hold options to purchase stock possessing five percent (5%) or more of the total combined voting power or value of all classes of stock
of the Company or its Parent or Subsidiary shall be granted an option to purchase Common Stock under this Plan. Notwithstanding the foregoing, the rules of Section 424(d) of the Code shall apply in determining share ownership and the extent to
which shares held under outstanding equity awards are to be treated as owned by the employee. 
 5. OFFERING DATES. 

(a) Each Offering Period of this Plan may be of up to twenty seven (27) months’ duration and shall commence and end at the times
designated by the Committee. Each Offering Period shall consist of one Purchase Period during which Contributions made by Participants are accumulated under this Plan. 

(b) The initial Offering Period shall commence on the Effective Date and shall end with the Purchase Date that occurs on June 30, 2016 or
another date selected by the Committee which is approximately six (6) months after the commencement of the initial Offering Period, but no more than twenty-seven (27) months after the commencement of the initial Offering Period. The
initial Offering Period shall consist of one Purchase Period. Thereafter, a six-month Offering Period shall commence on each January 1st and July 1st, with each such Offering Period also consisting of one six-month Purchase Period, except as otherwise provided by an applicable sub-plan, or on such other date determined by the Committee. The
Committee may at any time establish a different duration for an Offering Period or Purchase Period to be effective after the next scheduled Purchase Date, up to a maximum duration of twenty-seven (27) months. 

  
 - 2 - 

 6. PARTICIPATION IN THIS PLAN. 

(a) Any employee who is an eligible employee determined in accordance with Section 4 immediately prior to the initial Offering Period
will be automatically enrolled in the initial Offering Period under this Plan for the maximum number of shares of Common Stock purchasable. With respect to subsequent Offering Periods, any eligible employee determined in accordance with
Section 4 will be eligible to participate in this Plan, subject to the requirement of Section 6(b) hereof and the other terms and provisions of this Plan. 

(b) With respect to Offering Periods after the initial Offering Period, a Participant may elect to participate in this Plan by submitting an
enrollment agreement prior to the commencement of the Offering Period (or such earlier date as the Committee may determine) to which such agreement relates. 

(c) Once an employee becomes a Participant in an Offering Period, then such Participant will automatically participate in each subsequent
Offering Period commencing immediately following the last day of the prior Offering Period unless the Participant withdraws or is deemed to withdraw from this Plan or terminates further participation in an Offering Period as set forth in
Section 11 below. A Participant who is continuing participation pursuant to the preceding sentence is not required to file any additional enrollment agreement in order to continue participation in this Plan; a Participant who is not continuing
participation pursuant to the preceding sentence is required to file an enrollment agreement prior to the commencement of the Offering Period (or such earlier date as the Committee may determine) to which such agreement relates. 

7. GRANT OF OPTION ON ENROLLMENT. Becoming a Participant with respect to an Offering Period will constitute the grant (as of the
Offering Date) by the Company to such Participant of an option to purchase on the Purchase Date up to that number of shares of Common Stock of the Company determined by a fraction, the numerator of which is the amount accumulated in such
Participant’s Contribution account during such Purchase Period and the denominator of which is the lower of (i) eighty-five percent (85%) of the Fair Market Value of a share of Common Stock on the Offering Date (but in no event
less than the par value of a share of the Common Stock), or (ii) eighty-five percent (85%) of the Fair Market Value of a share of the Common Stock on the Purchase Date; provided, however, that for the Purchase Period within the
initial Offering Period the numerator shall be fifteen percent (15%) of the Participant’s compensation for such Purchase Period, or such lower percentage as determined by the Committee prior to the start of the Offering Period, and
provided, further, that the number of shares of Common Stock subject to any option granted pursuant to this Plan shall not exceed the lesser of (x) the maximum number of shares set by the Committee pursuant to Section 10(b)
below with respect to the applicable Purchase Date, or (y) the maximum number of shares which may be purchased pursuant to Section 10(a) below with respect to the applicable Purchase Date. 

8. PURCHASE PRICE. The Purchase Price per share at which a share of Common Stock will be sold in any Offering Period shall be
eighty-five percent (85%) of the lesser of: 
 (a) The Fair Market Value on the Offering Date; or 

(b) The Fair Market Value on the Purchase Date. 

9. PAYMENT OF PURCHASE PRICE; CONTRIBUTION CHANGES; SHARE ISSUANCES. 

(a) The Purchase Price shall be accumulated by regular payroll deductions made during each Offering Period, unless the Committee determines
with respect to categories of Participants outside the United States that Contributions may be made in another form due to local legal requirements. The Contributions are made as a percentage of the Participant’s Compensation in one percent
(1%)

  
 - 3 - 

 
increments not less than one percent (1%), nor greater than fifteen (15%) percent or such lower limit set by the Committee. “Compensation” shall mean base salary (or
in foreign jurisdictions, equivalent cash compensation); however, the Committee may at any time prior to the beginning of an Offering Period determine that for that and future Offering Periods, Compensation shall mean all cash compensation reported
on the employee’s Form W-2 or corresponding local country tax return, including without limitation base salary or regular hourly wages, bonuses, incentive compensation, commissions, overtime, shift premiums, and draws against commissions. For
purposes of determining a Participant’s Compensation, any election by such Participant to reduce his or her regular cash remuneration under Sections 125 or 401(k) of the Code (or in foreign jurisdictions, equivalent salary deductions)
shall be treated as if the Participant did not make such election. Contributions shall commence on the first payday following the last Purchase Date (with respect to the initial Offering Period, as soon as practicable following the effective date of
filing with the U.S. Securities and Exchange Commission a securities registration statement for the Plan) and shall continue to the end of the Offering Period unless sooner altered or terminated as provided in this Plan. Notwithstanding the
foregoing, the terms of any sub-plan may permit matching shares without the payment of any purchase price. 
 (b) A Participant may decrease
the rate of Contributions during an Offering Period by filing with the Company or a third party designated by the Company a new authorization for Contributions, with the new rate to become effective no later than the second payroll period commencing
after the Company’s receipt of the authorization and continuing for the remainder of the Offering Period unless changed as described below. A decrease in the rate of Contributions may be made once during an Offering Period, but up to twice
during the initial Offering Period, or more frequently under rules determined by the Committee. A Participant may increase or decrease the rate of Contributions for any subsequent Offering Period by filing with the Company or a third party
designated by the Company a new authorization for Contributions prior to the beginning of such Offering Period, or such other time period as specified by the Committee. 

(c) A Participant may reduce his or her Contribution percentage to zero during an Offering Period by filing with the Company or a third party
designated by the Company a request for cessation of Contributions. Such reduction shall be effective beginning no later than the second payroll period after the Company’s receipt of the request and no further Contributions will be made for the
duration of the Offering Period. Contributions credited to the Participant’s account prior to the effective date of the request shall be used to purchase shares of Common Stock in accordance with Subsection (e) below. A reduction of the
Contribution percentage to zero shall be treated as such Participant’s withdrawal from such Offering Period and the Plan, effective as of the day after the next Purchase Date following the filing date of such request with the Company. 

(d) All Contributions made for a Participant are credited to his or her book account under this Plan and are deposited with the general funds
of the Company, except to the extent local legal restrictions outside the United States require segregation of such Contributions. No interest accrues on the Contributions, except to the extent required due to local legal requirements. All
Contributions received or held by the Company may be used by the Company for any corporate purpose, and the Company shall not be obligated to segregate such Contributions, except to the extent necessary to comply with local legal requirements
outside the United States. 
 (e) On each Purchase Date, so long as this Plan remains in effect and provided that the Participant has not
submitted a signed and completed withdrawal form before that date which notifies the Company that the Participant wishes to withdraw from that Offering Period under this Plan and have all Contributions accumulated in the account maintained on behalf
of the Participant as of that date returned to the Participant, the Company shall apply the funds then in the Participant’s account to the purchase of whole shares of Common Stock reserved under the option granted to such Participant with
respect to the Offering Period to the extent that such option is exercisable on the Purchase Date. The Purchase Price per share shall be as specified in Section 8 of this Plan. Any fractional share, as calculated under this Subsection (e),
shall be rounded down to the next lower whole share, unless the Committee 

  
 - 4 - 

 
determines with respect to all Participants that any fractional share shall be credited as a fractional share. Any amount remaining in a Participant’s account on a Purchase Date that is less
than the amount necessary to purchase a full share of Common Stock shall be returned to the Participant, without interest (except to the extent necessary to comply with local legal requirements outside the United States); however, the Committee may
provide that such amounts may be carried forward into the next Purchase Period or Offering Period, as the case may be. In the event that this Plan has been oversubscribed, all funds not used to purchase shares on the Purchase Date shall be returned
to the Participant, without interest (except to the extent required due to local legal requirements outside the United States). No Common Stock shall be purchased on a Purchase Date on behalf of any employee whose participation in this Plan has
terminated prior to such Purchase Date, except to the extent required due to local legal requirements outside the United States. 
 (f) As
promptly as practicable after the Purchase Date, the Company shall issue shares for the Participant’s benefit representing the shares purchased upon exercise of his or her option to purchase shares hereunder. 

(g) During a Participant’s lifetime, his or her option to purchase shares hereunder is exercisable only by him or her. The Participant
will have no interest or voting right in shares covered by his or her option until such option has been exercised. 
 (h) To the extent
required by applicable federal, state, local or foreign law, a Participant shall make arrangements satisfactory to the Company and the Participating Corporation employing the Participant for the satisfaction of any withholding tax obligations that
arise in connection with the Plan. The Company or any Subsidiary or Affiliate, as applicable, may withhold, by any method permissible under the applicable law, the amount necessary for the Company or Subsidiary or Affiliate, as applicable, to meet
applicable withholding obligations, including any withholding required to make available to the Company or Subsidiary or Affiliate, as applicable, any tax deductions or benefits attributable to the sale or early disposition of shares of Common Stock
by a Participant. The Company shall not be required to issue any shares of Common Stock under the Plan until such obligations are satisfied. 

10. LIMITATIONS ON SHARES TO BE PURCHASED. 

(a) Any other provision of the Plan notwithstanding, no Participant shall purchase Common Stock with a Fair Market Value in excess of the
following limit: 
 (i) In the case of Common Stock purchased during an Offering Period that commenced in the current calendar year, the
limit shall be equal to (A) $25,000 minus (B) the Fair Market Value of the Common Stock that the Participant previously purchased in the current calendar year (under this Plan and all other employee stock purchase plans of the Company or
any Parent or Subsidiary). 
 (ii) In the case of Common Stock purchased during an Offering Period that commenced in the immediately
preceding calendar year, the limit shall be equal to (A) $50,000 minus (B) the Fair Market Value of the Common Stock that the Participant previously purchased (under this Plan and all other employee stock purchase plans of the Company or
any Parent or Subsidiary) in the current calendar year and in the immediately preceding calendar year. 
 For purposes of this Subsection (a), the Fair
Market Value of Common Stock shall be determined in each case as of the beginning of the Offering Period in which such Common Stock is purchased. Employee stock purchase plans not described in Section 423 of the Code shall be disregarded. If a
Participant is precluded by this Subsection (a) from purchasing additional Common Stock under the Plan, then his or her Contributions shall automatically be discontinued and shall automatically resume at the beginning of the earliest Purchase
Period that will end in the next calendar year (if he or she then is an eligible 

  
 - 5 - 

 
employee), provided that when the Company automatically resumes such Contributions, the Company must apply the rate in effect immediately prior to such suspension. 

(b) In no event shall a Participant be permitted to purchase more than 2500 shares on any one Purchase Date, or such lesser number as the
Committee shall determine. If a lower limit is set under this Subsection (b), then all Participants will be notified of such limit prior to the commencement of the next Offering Period for which it is to be effective. 

(c) If the number of shares to be purchased on a Purchase Date by all Participants exceeds the number of shares then available for issuance
under this Plan, then the Company will make a pro rata allocation of the remaining shares in as uniform a manner as shall be reasonably practicable and as the Committee shall determine to be equitable. In such event, the Company will give notice of
such reduction of the number of shares to be purchased under a Participant’s option to each Participant affected. 
 (d) Any
Contributions accumulated in a Participant’s account that are not used to purchase stock due to the limitations in this Section 10, and not subject to the automatic purchase provision of Section 9(e), shall be returned to the
Participant as soon as practicable after the end of the applicable Purchase Period, without interest (except to the extent required due to local legal requirements outside the United States). 

11. WITHDRAWAL. 
 (a)
Each Participant may withdraw from an Offering Period under this Plan pursuant to a method specified for such purpose by the Company. Such withdrawal may be elected at any time prior to the end of an Offering Period, or such other time period as
specified by the Committee. 
 (b) Upon withdrawal from this Plan, the accumulated Contributions shall be returned to the withdrawn
Participant, without interest (except to the extent required due to local legal requirements outside the United States), and his or her interest in this Plan shall terminate. In the event a Participant voluntarily elects to withdraw from this Plan,
he or she may not resume his or her participation in this Plan during the same Offering Period, but he or she may participate in any Offering Period under this Plan which commences on a date subsequent to such withdrawal by filing a new
authorization for Contributions in the same manner as set forth in Section 6 above for initial participation in this Plan. 
 12.
TERMINATION OF EMPLOYMENT. Termination of a Participant’s employment for any reason, including retirement, death, disability, or the failure of a Participant to remain an eligible employee of the Company or of a Participating Corporation,
immediately terminates his or her participation in this Plan (except as required due to local legal requirements outside the United States). In such event, accumulated Contributions credited to the Participant’s account will be returned to him
or her or, in the case of his or her death, to his or her legal representative, without interest (except to the extent required due to local legal requirements outside the United States). For purposes of this Section 12, an employee will not be
deemed to have terminated employment or failed to remain in the continuous employ of the Company or of a Participating Corporation in the case of sick leave, military leave, or any other leave of absence approved by the Company; provided that
such leave is for a period of not more than ninety (90) days or reemployment upon the expiration of such leave is guaranteed by contract or statute. The Company will have sole discretion to determine whether a Participant has terminated
employment and the effective date on which the Participant terminated employment, regardless of any notice period or garden leave required under local law. 

13. RETURN OF CONTRIBUTIONS. In the event a Participant’s interest in this Plan is terminated by withdrawal, termination of
employment or otherwise, or in the event this Plan is terminated by the Board, the Company shall deliver to the Participant all accumulated Contributions credited to such 

  
 - 6 - 

 
Participant’s account. No interest shall accrue on the Contributions of a Participant in this Plan (except to the extent required due to local legal requirements outside the United States).

 14. CAPITAL CHANGES. If the number of outstanding shares is changed by a stock dividend, recapitalization, stock split, reverse
stock split, subdivision, combination, reclassification or similar change in the capital structure of the Company, without consideration, then the Committee shall adjust the number and class of Common Stock that may be delivered under the Plan, the
Purchase Price per share and the number of shares of Common Stock covered by each option under the Plan which has not yet been exercised, and the numerical limits of Sections 2 and 10 shall be proportionately adjusted, subject to any required
action by the Board or the stockholders of the Company and in compliance with the applicable securities laws; provided that fractions of a share will not be issued. 

15. NONASSIGNABILITY. Neither Contributions credited to a Participant’s account nor any rights with regard to the exercise of an
option or to receive shares under this Plan may be assigned, transferred, pledged or otherwise disposed of in any way (other than by will, the laws of descent and distribution or as provided in Section 22 below) by the Participant. Any such
attempt at assignment, transfer, pledge or other disposition shall be void and without effect. 
 16. USE OF PARTICIPANT FUNDS AND
REPORTS. The Company may use all Contributions received or held by it under the Plan for any corporate purpose, and the Company will not be required to segregate Participant Contributions (except to the extent required due to local legal
requirements outside the United States). Until shares are issued, Participants will only have the rights of an unsecured creditor unless otherwise required under local law. Each Participant shall receive promptly after the end of each Purchase
Period a report of his or her account setting forth the total Contributions accumulated, the number of shares purchased, the per share price thereof and the remaining cash balance, if any, carried forward to the next Purchase Period or Offering
Period, as the case may be. 
 17. NOTICE OF DISPOSITION. Each U.S. taxpayer Participant shall notify the Company in writing if the
Participant disposes of any of the shares purchased in any Offering Period pursuant to this Plan if such disposition occurs within two (2) years from the Offering Date or within one (1) year from the Purchase Date on which such shares were
purchased (the “Notice Period”). The Company may, at any time during the Notice Period, place a legend or legends on any certificate representing shares acquired pursuant to this Plan requesting the Company’s transfer
agent to notify the Company of any transfer of the shares. The obligation of the Participant to provide such notice shall continue notwithstanding the placement of any such legend on the certificates. 

18. NO RIGHTS TO CONTINUED EMPLOYMENT. Neither this Plan nor the grant of any option hereunder shall confer any right on any employee
to remain in the employ of the Company or any Participating Corporation, or restrict the right of the Company or any Participating Corporation to terminate such employee’s employment. 

19. EQUAL RIGHTS AND PRIVILEGES. All eligible employees granted an option under the Section 423 Component of this Plan shall have
equal rights and privileges with respect to this Plan or within any separate offering under the Plan so that this Plan qualifies as an “employee stock purchase plan” within the meaning of Section 423 or any successor provision of the
Code and the related regulations. Any provision of this Plan which is inconsistent with Section 423 or any successor provision of the Code, without further act or amendment by the Company, the Committee or the Board, shall be reformed to comply
with the requirements of Section 423. This Section 19 shall take precedence over all other provisions in this Plan. 
 20.
NOTICES. All notices or other communications by a Participant to the Company under or in connection with this Plan shall be deemed to have been duly given when received in the form specified by the Company at the location, or by the person,
designated by the Company for the receipt thereof. 

  
 - 7 - 

 21. TERM; STOCKHOLDER APPROVAL. This Plan will become effective on the Effective Date.
This Plan shall be approved by the stockholders of the Company, in any manner permitted by applicable corporate law, within twelve (12) months before or after the date this Plan is adopted by the Board. No purchase of shares that are subject to
such stockholder approval before becoming available under this Plan shall occur prior to stockholder approval of such shares and the Board or Committee may delay any Purchase Date and postpone the commencement of any Offering Period subsequent to
such Purchase Date as deemed necessary or desirable to obtain such approval (provided that if a Purchase Date would occur more than twenty-seven (27) months after commencement of the Offering Period to which it relates, then such Purchase Date
shall not occur and instead such Offering Period shall terminate without the purchase of such shares and Participants in such Offering Period shall be refunded their Contributions without interest). This Plan shall continue until the earlier to
occur of (a) termination of this Plan by the Board (which termination may be effected by the Board at any time pursuant to Section 25 below), (b) issuance of all of the shares of Common Stock reserved for issuance under this Plan, or
(c) the tenth anniversary of the Effective Date under the Plan. 
 22. DESIGNATION OF BENEFICIARY. 

(a) Unless otherwise determined by the Committee, a Participant may file a written designation of a beneficiary who is to receive any cash
from the Participant’s account under this Plan in the event of such Participant’s death prior to a Purchase Date. Such form shall be valid only if it was filed with the Company at the prescribed location before the Participant’s
death. 
 (b) If authorized by the Company, such designation of beneficiary may be changed by the Participant at any time by written notice
filed with the Company at the prescribed location before the Participant’s death. In the event of the death of a Participant and in the absence of a beneficiary validly designated under this Plan who is living at the time of such
Participant’s death, the Company shall deliver such cash to the executor or administrator of the estate of the Participant or to the legal heirs of the Participant. 

23. CONDITIONS UPON ISSUANCE OF SHARES; LIMITATION ON SALE OF SHARES. Shares shall not be issued with respect to an option unless the
exercise of such option and the issuance and delivery of such shares pursuant thereto shall comply with all applicable provisions of law, domestic or foreign, including, without limitation, the U.S. Securities Act of 1933, as amended, the U.S.
Securities Exchange Act of 1934, as amended, the rules and regulations promulgated thereunder, and the requirements of any stock exchange or automated quotation system upon which the shares may then be listed, exchange control restrictions and/or
securities law restrictions outside the United States, and shall be further subject to the approval of counsel for the Company with respect to such compliance. Shares may be held in trust or subject to further restrictions as permitted by any
subplan. 
 24. APPLICABLE LAW. The Plan shall be governed by the substantive laws (excluding the conflict of laws rules) of the
State of Delaware. 
 25. AMENDMENT OR TERMINATION. The Committee, in its sole discretion, may amend, suspend, or terminate the Plan,
or any part thereof, at any time and for any reason. Unless otherwise required by applicable law, if the Plan is terminated, the Committee, in its discretion, may elect to terminate all outstanding Offering Periods either immediately or upon
completion of the purchase of shares of Common Stock on the next Purchase Date (which may be sooner than originally scheduled, if determined by the Committee in its discretion), or may elect to permit Offering Periods to expire in accordance with
their terms (and subject to any adjustment pursuant to Section 14). If an Offering Period is terminated prior to its previously-scheduled expiration, all amounts then credited to Participants’ accounts for such Offering Period, which have
not been used to purchase shares of Common Stock, shall be returned to those Participants (without interest thereon, except as otherwise required under local laws) as soon as administratively practicable. Further, the Committee will be entitled to
change the Purchase Periods and Offering Periods, limit the frequency and/or number of changes in the amount contributed 

  
 - 8 - 

 
during an Offering Period, establish the exchange ratio applicable to amounts contributed in a currency other than U.S. dollars, permit payroll withholding in excess of the amount designated by a
Participant in order to adjust for delays or mistakes in the administration of the Plan, establish reasonable waiting and adjustment periods and/or accounting and crediting procedures to ensure that amounts applied toward the purchase of Common
Stock for each Participant properly correspond with amounts contributed from the Participant’s base salary and other eligible compensation, and establish such other limitations or procedures as the Committee determines in its sole discretion
advisable which are consistent with the Plan. Such actions will not require stockholder approval or the consent of any Participants. However, no amendment shall be made without approval of the stockholders of the Company (obtained in accordance with
Section 21 above) within twelve (12) months of the adoption of such amendment (or earlier if required by Section 21) if such amendment would: (a) increase the number of shares that may be issued under this Plan; or
(b) change the designation of the employees (or class of employees) eligible for participation in this Plan. In addition, in the event the Board or Committee determines that the ongoing operation of the Plan may result in unfavorable financial
accounting consequences, the Board or Committee may, in its discretion and, to the extent necessary or desirable, modify, amend or terminate the Plan to reduce or eliminate such accounting consequences including, but not limited to:
(i) amending the definition of compensation, including with respect to an Offering Period underway at the time; (ii) altering the Purchase Price for any Offering Period including an Offering Period underway at the time of the change in
Purchase Price; (iii) shortening any Offering Period by setting a Purchase Date, including an Offering Period underway at the time of the Committee’s action; (iv) reducing the maximum percentage of Compensation a participant may elect
to set aside as Contributions; and (v) reducing the maximum number of shares a Participant may purchase during any Offering Period. Such modifications or amendments will not require approval of the stockholders of the Company or the consent of
any Participants. 
 26. CORPORATE TRANSACTIONS. In the event of a Corporate Transaction, the Offering Period for each outstanding
right to purchase Common Stock will be shortened by setting a new Purchase Date and will end on the new Purchase Date. The new Purchase Date shall occur on or prior to the consummation of the Corporate Transaction, as determined by the Board or
Committee, and the Plan shall terminate on the consummation of the Corporate Transaction. 
 27. CODE SECTION 409A; TAX QUALIFICATION.

 (a) Options granted under the Plan generally are exempt from the application of Section 409A of the Code. However, options
granted to U.S. taxpayers which are not intended to meet the Code Section 423 requirements are intended to be exempt from the application of Section 409A of the Code under the short-term deferral exception and any ambiguities shall be
construed and interpreted in accordance with such intent. Subject to Subsection (b), options granted to U.S. taxpayers outside of the Code Section 423 requirements shall be subject to such terms and conditions that will permit such options to
satisfy the requirements of the short-term deferral exception available under Section 409A of the Code, including the requirement that the shares of Common Stock subject to an option be delivered within the short-term deferral period. Subject
to Subsection (b), in the case of a Participant who would otherwise be subject to Section 409A of the Code, to the extent the Committee determines that an option or the exercise, payment, settlement or deferral thereof is subject to
Section 409A of the Code, the option shall be granted, exercised, paid, settled or deferred in a manner that will comply with Section 409A of the Code, including Treasury regulations and other interpretive guidance issued thereunder,
including without limitation any such regulations or other guidance that may be issued after the Effective Date. Notwithstanding the foregoing, the Company shall have no liability to a Participant or any other party if the option that is intended to
be exempt from or compliant with Section 409A of the Code is not so exempt or compliant or for any action taken by the Committee with respect thereto. 

(b) Although the Company may endeavor to (i) qualify an option for favorable tax treatment under the laws of the United States or
jurisdictions outside of the United States or (ii) avoid adverse tax treatment (e.g., under Section 409A of the Code), the Company makes no representation to 

  
 - 9 - 

 
that effect and expressly disavows any covenant to maintain favorable or avoid unfavorable tax treatment, notwithstanding anything to the contrary in this Plan, including Subsection (a). The
Company shall be unconstrained in its corporate activities without regard to the potential negative tax impact on Participants under the Plan. 

28. DEFINITIONS. 
 (a)
“Affiliate” means any entity, other than a Subsidiary or Parent, (i) that, directly or indirectly, is controlled by, controls or is under common control with, the Company and (ii) in which the Company has a
significant equity interest, in either case as determined by the Committee, whether now or hereafter existing. 
 (b)
“Board” shall mean the Board of Directors of the Company. 
 (c) “Code” shall mean the U.S.
Internal Revenue Code of 1986, as amended. 
 (d) “Committee” shall mean the Compensation Committee of the Board
that consists exclusively of one or more members of the Board appointed by the Board. 
 (e) “Common Stock” shall
mean the common stock of the Company. 
 (f) “Company” shall mean Adesto Technologies Corporation. 

(g) “Contributions” means payroll deductions taken from a Participant’s Compensation and used to purchase shares
of Common Stock under the Plan and, to the extent payroll deductions are not permitted by applicable laws (as determined by the Committee in its sole discretion) contributions by other means, provided, however, that allowing such other contributions
does not jeopardize the qualification of the Plan as an “employee stock purchase plan” under Section 423 of the Plan. 
 (h)
“Corporate Transaction” means the occurrence of any of the following events: (i) any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becomes the “beneficial owner”
(as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company’s then outstanding voting securities; or
(ii) the consummation of the sale or disposition by the Company of all or substantially all of the Company’s assets; or (iii) the consummation of a merger or consolidation of the Company with any other corporation, other than a merger
or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its
parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation. 

(i) “Effective Date” shall mean the date on which the Registration Statement covering the initial public offering of
the shares of Common Stock is declared effective by the U.S. Securities and Exchange Commission. 
 (j) “Fair Market
Value” shall mean, as of any date, the value of a share of Common Stock determined as follows: 
 (1) if such Common Stock is
then quoted on the Nasdaq Global Select Market, the Nasdaq Global Market or the Nasdaq Capital Market (collectively, the “Nasdaq Market”), its closing price on the Nasdaq Market on the date of determination, or if there are
no sales for such date, 

  
 - 10 - 

 
then the last preceding business day on which there were sales, as reported in The Wall Street Journal or such other source as the Board or the Committee deems reliable; or 

(2) if such Common Stock is publicly traded and is then listed on a national securities exchange, its closing price on the date of
determination on the principal national securities exchange on which the Common Stock is listed or admitted to trading as reported in The Wall Street Journal or such other source as the Board or the Committee deems reliable; or 

(3) if such Common Stock is publicly traded but is neither quoted on the Nasdaq Market nor listed or admitted to trading on a national
securities exchange, the average of the closing bid and asked prices on the date of determination as reported in The Wall Street Journal or such other source as the Board or the Committee deems reliable; or 

(4) with respect to the initial Offering Period, Fair Market Value on the Offering Date shall be the price at which shares of Common Stock
are offered to the public pursuant to the Registration Statement covering the initial public offering of shares of Common Stock; or 
 (5)
if none of the foregoing is applicable, by the Board or the Committee in good faith. 
 (k) “IPO” shall mean the
initial public offering of Common Stock. 
 (l) “Non-Section 423 Component” means the part of the Plan which is
not intended to meet the requirements set forth in Section 423 of the Code. 
 (m) “Notice Period” shall mean
within two (2) years from the Offering Date or within one (1) year from the Purchase Date on which such shares were purchased. 

(n) “Offering Date” shall mean the first business day of each Offering Period. However, for the initial Offering
Period the Offering Date shall be the Effective Date. 
 (o) “Offering Period” shall mean a period with respect to
which the right to purchase Common Stock may be granted under the Plan, as determined by the Committee pursuant to Section 5(a). 
 (p)
“Parent” shall have the same meaning as “parent corporation” in Sections 424(e) and 424(f) of the Code. 

(q) “Participant” shall mean an eligible employee who meets the eligibility requirements set forth in Section 4
and who is either automatically enrolled in the initial Offering Period or who elects to participate in this Plan pursuant to Section 6(b). 

(r) “Participating Corporation” shall mean any Parent, Subsidiary or Affiliate that the Committee designates from time
to time as eligible to participate in this Plan. For purposes of the Section 423 Component, only the Parent and Subsidiaries may be Participating Corporations, provided, however, that at any given time a Parent or Subsidiary that is a
Participating Corporation under the Section 423 Component shall not be a Participating Corporation under the Non-Section 423 Component. The Committee may provide that any Participating Corporation shall only be eligible to participate in
the Non-Section 423 Component. 
 (s) “Plan” shall mean this Adesto Technologies Corporation 2015 Employee
Stock Purchase Plan, as may be amended from time to time. 
 (t) “Purchase Date” shall mean the last business day of
each Purchase Period. 

  
 - 11 - 

 (u) “Purchase Period” shall mean a period during which Contributions may
be made toward the purchase of Common Stock under the Plan, as determined by the Committee pursuant to Section 5(b). 
 (v)
“Purchase Price” shall mean the price at which Participants may purchase shares of Common Stock under the Plan, as determined pursuant to Section 8. 

(w) “Section 423 Component” means the part of the Plan, which excludes the Non-Section 423 Component, pursuant to
which options to purchase shares of Common Stock under the Plan that satisfy the requirements for “employee stock purchase plans” set forth in Section 423 of the Code may be granted to eligible employees. 

(x) “Subsidiary” shall have the same meaning as “subsidiary corporation” in Sections 424(e) and 424(f)
of the Code. 

  
 - 12 - 

			
	ADESTO TECHNOLOGIES CORPORATION (THE “COMPANY”)	  	U.S. FORM
	2015 EMPLOYEE STOCK PURCHASE PLAN (“ESPP”)	  	ENROLLMENT/CHANGE FORM

  

					
	SECTION 1:	  	CHECK DESIRED ACTION:	  	AND COMPLETE SECTIONS:
	  
 ACTIONS
	  	  

 ̈    Enroll in the ESPP
	  	  
 2 + 3 + 4 + 7

		  	 ̈    Elect / Change Contribution Percentage	  	2 + 4 + 7
		  	 ̈    Discontinue Contributions	  	2 + 5 + 7

  

							
	SECTION 2:	  	Name:	  	  

							
			
	PERSONAL DATA	  	Home Address:	  	  

							
		
		  	  

		  	Social Security No.:  ̈ ̈ ̈- ̈ ̈- ̈ ̈ ̈ ̈	  	

  

			
	 SECTION 3:
  

ENROLL
	  	 ̈  I hereby elect to participate in the ESPP, effective at the beginning of the next Offering Period. I elect to purchase shares of the Common Stock of the Company pursuant
to the ESPP. I understand that the stock certificate(s) for the shares purchased on my behalf will be issued in street name and deposited directly into my brokerage account. I hereby agree to take all steps, and sign all forms, required to establish
an account with the Company’s broker for this purpose.
		
		  	My participation will continue as long as I remain eligible, unless I withdraw from the ESPP by filing a new Enrollment/Change Form with the Company. I understand that I must notify the Company of any disposition of shares purchased
under the ESPP.

  

			
	 SECTION 4:
  

ELECT/CHANGE

CONTRIBUTION

PERCENTAGE
	  	I hereby authorize the Company to withhold from each of my paychecks such amount as is necessary to equal at the end of the applicable Offering Period     % of my Compensation (as provided in Section 9 of the
ESPP) paid during such Offering Period as long as I continue to participate in the ESPP. That amount, plus any accumulated payroll deductions thus far during the current Offering Period if this is a change, will be applied to the purchase of shares
of the Common Stock pursuant to the ESPP. The percentage must be a whole number (from 1%, up to a maximum of 15%, with respect to enrollment or an increase in contribution percentage; from 0%, up to a maximum of 14% for a decrease in contribution
percentage).
		
		  	If this is a change to my current enrollment, this represents an  ̈-increase  ̈-decrease to my contribution percentage.
		
		  	 Note:   You may not increase your contribution at any time within an Offering Period. You may decrease your
contribution percentage to a percentage other than 0% only once within an Offering Period, but up to twice during the initial Offering Period, to be effective during that Offering Period. A change will become effective as soon as reasonably
practicable after the form is received by the Company. An increase in your contribution percentage can only take effect with the next Offering Period.

  

					
	 SECTION 5:
  

DISCONTINUE

CONTRIBUTIONS
	 	 ̈	  	I hereby elect to stop my contributions under the ESPP, effective as soon as reasonably practicable after this form is received by the Company. Accumulated payroll deductions will be returned to me without interest, pursuant
to Section 11 of the ESPP.

					
	 SECTION 6:
  

ELECTRONIC DELIVERY AND ACCEPTANCE
	  	The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the ESPP by electronic means. I hereby consent to receive such documents by electronic delivery and
agree to participate in the ESPP through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.

					
		
	 SECTION 7:
  

ACKNOWLEDGMENT

AND SIGNATURE
	  	I acknowledge that I have received a copy of the ESPP Prospectus (which summarizes the major features of the ESPP). I have read the Prospectus and my signature below indicates that I hereby agree to be bound by the terms
of the ESPP.

									
		 	   Signature:	 	  
	  	Date:Exhibit 10.20

 

PHARMACEUTICAL LICENSE
AGREEMENT

 

This AGREEMENT dated as of October 1,
2012, is made by and between Blue Ivory Holdings Ltd., corporation incorporated pursuant to the laws of Bahamas, having its principal
place of business at Nassau, Bahamas ("licensor"} and Axxess Pharma Inc.. a corporation incorporated pursuant to the
laws of Nevada, having its principal place of business at 2681 Eglinton ave West,Toronto, Ontario. M6M 1T8. Canada("licensee").

 

WHEREAS
Licensor is the beneficial Owner of certain Drug Identification Numbers registered with Health Canada (the "DINs") as
listed in Schedule "A" hereto, as amended from time to time. Licensee desires to
license from Licensor the right to develop, market, make, use, and sell certain drug formulations which are applied to humans
through the use of the DINs. In consideration of the mutual covenants and promises contained in this Agreement and other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, licensor and Licensee agree as follows:

 

I. Definitions

 

As used in this Agreement, the following
terms, whether used in the singular or plural, shall have the following meanings;

 

L 1. "Drug
Technology" means any technology owned or licensable by Licensor which relates to the DINs.

 

1.2. "licensor Patent Rights"
means all patents and patent applications (which for all purposes of this Agreement shall be deemed to include certificates of
invention, applications for certificates of invention, and utility models) throughout the world, covering or relating to the Drug
Technology, including any substitutions. extensions, reissues, reexaminations, renewals, divisions, continuations. or continuations-in-part,
which licensor owns or controls, and under which Licensor has the right to grant sublicenses to licensee, as of the date of this
Agreement. All current patents

 

     

     

    

 

1.5. "Field" means the DINs
formulations, including but not limited to those listed in Schedule C.

 

1.6. ''licensed Products" means a
product which, or the manufacture, use, or sale of which, is covered by a DIN listed in Schedule "A''.

 

1.7. "Net Sales" shall mean
the gross amount actually received by Licensee on sales of Licensed Products, less: {a) credits or allowances, if any, actually
granted: (b) discounts actually allowed; (c) freight, postage, and insurance charges and additional special packaging charges;
and (d) customs duties, and excises, sales. taxes, duties or other taxed imposed upon and paid with respect to such sales (excluding
what is commonly known as income taxes). In the case of any Licensed Products supplied to Licensee by Licensor, "Net Sales"
shall mean the amount as defined in the preceding sentence, less the amount paid by Licensee to Licensor for Licensor to supply
the Licensed Products.

 

1.8. "Party" means Licensee
or Licensor; "Parties'' means Licensee and Licensor.

 

1.9. "Valid Claim" means a claim
of any unexpired United States or foreign patent or patent application which shall not have been withdrawn. canceled, or disclaimed,
nor held invalid by a court of competent jurisdiction in an unappeafed or unappealable decision.

 

II. License

 

11.1. License.
Subject to the payment of the royalties provided in Article Ill and the fulfillment of the other terms and conditions of this
Agreement, Licensor hereby grants to Licensee a worldwide, exclusive license under all of the Licensor Patent Rights and Licensor
Technology Rights, including the right to sublicense any or all of such rights, to make, have made. use, have used, sell, and
have sold the Drug Technology.

 

11.2. Assistance. Licensor shall provide
Licensee with all information related to the licensor Patent Rights and Licensor Technology Rights as may be known or possessed
by Licensor and as may be reasonably necessary for Licensee to exploit the licenses granted in Section 2.1., including any

 

     

     

    

 

The Licensee shall pay as a licensee Fee
the sum of Five Million Dollars ($5,000.000.00) payable in quarterly instalments of One Hundred and Twenty Five Thousand Dollars
($125,000.00) payable over a period of Ten (10) years.

 

111.3. Sublicense Fees. Licensee shall
pay to licensor Ten (10) percent (10%) of all royalties and sublicense fees paid to Licensee on account of sublicenses for the
sale of the Licensed Products.

 

IV. Representations, Warranties, and Covenants

 

IV.1. Representations and Warranties of
Licensor. Licensor hereby represents and warrants that: (i) Licensor has the authority to grant to Licensee all of the rights
granted hereunder; (ii) Licensor owns or controls all rights to the Licensor Patent Rights and the Licensor Technology Rights;
and (iii) Licensor is unaware of any rights superior to Licensor's in the Drug Technology which would prevent Licensee from fully
exercising the rights licensed to it herein.

 

IV.2. Covenant of licensee. Licensee hereby
covenants and agrees to use reasonable efforts to develop, and obtain all necessary regulatory approvals for, and commercialize
certain formulations which can be delivered to humans through Licensed Products. In the event that Licensee breaches its obligations
under this Section 4.2, Licensee shall not be liable for any damages or other compensation as a result thereof, and Licensor'
sole and exclusive remedy shall be the termination of this Agreement pursuant to Section 7.2.

 

V. Intellectual Property Rights

 

V.i. Ownership.
Licensor shall own the entire right, title, and interest in and to all Licensor Patent Rights and Licensor Technology Rights.

 

     

     

    

 

V.2.
Right of Licensee to Prosecute Applications. licensor agrees that during the term of this Agreement, Licensor shall provide Licensee
with copies of all substantive communications to and from patent offices regarding applications or patents relating to the Drug
Technology promptly after the receipt thereof. Copies of proposed substantive communications to such patent offices shall be misappropriation.
Within 30 days after Licensor becomes, or is made, aware of any of the foregoing, it shall decide whether or not to initiate an
infringement or other appropriate suit and shall advise Licensee of its decision in writing. The inability of Licensor to decide
on a course of action within such 30 day period shall for purposes of this Agreement deemed a decision not to initiate an infringement
or other appropriate suit

 

(b) Within sixty (60)
days after Licensor becomes, or is made, aware of any infringement, suspected infringement or unauthorized use or misappropriation
by a third party in the Field, as provided in paragraph (a) above, and provided that Licensor shall have advised Licensee of its
decision to file suit within the 30 day period provided in paragraph (a} above, Licensor shall have the right to initiate an infringement
or other appropriate suit anywhere in the world against such third party. Licensor shall provide Licensee with an opportunity
to make suggestions and comments regarding such suit and shall promptly notify Licensee of the commencement of such suit Licensor
shall keep Licensee promptly informed of, and shall from time to time consult with Licensee regarding, the status of any such
suit and shall provide Licensee with copies of all documents filed in, and all written communications relating to, such suit

 

(c) Licensor shall
select counsel for any suit referred to in paragraph (b) above who shall be reasonably acceptable to Licensee. Licensor shall,
except as provided below, pay all expenses of the suit, including, without limitation, attorneys' fees and court costs. Licensee,
in its sole discretion, may elect. within 60 days after the receipt by Licensee from Licensor of notice of the commencement of
such litigation, to contribute to the costs incurred by Licensor in connection with such litigation in an amount not to exceed
50 percent of such costs. Any damages, settlement fees or other consideration for past infringement received as a result of such
litigation shall be shared by Licensor and Licensee pro rata based on their respective sharing of the costs of such litigation.
If necessary Licensee shall join as a party to the suit but shall be under no obligation to participate except to the extent that
such participation is required as the result of being a named party to the suit Licensee shall have the right to participate and
be represented in any suit by its own counsel at its own expense. Licensor shall not settle any such suit involving rights of
Licensee without obtaining the prior written consent of Licensee, which consent shall not be unreasonably withheld.

 

(d}
In the event that Licensor does not inform Licensee of its intent to initiate an infringement or other appropriate suit within
the 30-day period provided in paragraph (a) above, or does not initiate such an infringement other appropriate action within the
60-day period provided in served. At the request of Licensee, Licensor shall provide to Licensee advice regarding the technical
merits of any such claim.

 

     

     

    

 

(b) Licensor shall
defend Licensee at Licensor' cost and expense. and will indemnify and hold harmless Licensee, from and against any and all claims,
losses, costs, damages, fees and expenses arising out of or in connection with the infringement or alleged infringement by a Licensed
Product of any United States or foreign patent, copyright. trade secret or other intellectual property right of any third party
and any settlements relating thereto, provided that Licensor shall have sole control and authority with respect to the defense
or settlement of any such claim or action and Licensee shall cooperate fully with licensor in the defense or settlement of any
such claim or action. In the event that any Licensed Product becomes, or in Licensor's opinion is likely to become, the subject
of a claim of infringement of any United States or foreign patent, copyright, trade secret or other intellectual property right
of any third party, Licensor may at its option either secure for Licensee the right to continue using the Licensed Product, replace
or modify the Licensed Product to make it non-infringing without impairment of function or if neither of the foregoing alternatives
is reasonably available to Licensor, terminate Licensee's rights and licenses to the Licensed Product under this Agreement and
refund to Licensee all amounts paid by Licensee to Licensor depreciated on a five year straight line basis.

 

(c) The provisions
of Section 5.5(b) notwithstanding, Licensor shall not have any liability under Section 5.5(b) to the extent that any infringement
or claim results from: (i) use of the Licensed Product in combination with some other product or pharmaceutical formulation not
supplied by Licensor where the Licensed Product itself would not be infringing; or (ii) modifications of the Licensed Product where
the Licensed Product, if not modified by or for Licensee, would not be infringing.

 

(d) Except as otherwise
provided in this paragraph (d), if Licensee or any of its sublicensees, in order to operate under or exploit the license granted
under Article II of this Agreement in any country, must, in Licensee's or its sublicensee's reasonable judgment, make payments
to one or more third parties to obtain a license or similar right under a patent or other technology in the absence of which Licensed
Products could not legally be developed, manufactured, used, marketed or sold in such country, such third party payments shall
reduce and be set off against the royalty payments or sublicense fees otherwise due to Licensor in such country. Any payments
by Licensee or any of its sublicensees to one or more third parties to

 

     

     

    

 

Vl.2. Release from Restrictions. The provisions
of Section 6.1 shall not apply to any Confidential Information disclosed hereunder which:

 

(a) was known or used by the receiving
Party prior to its date of disclosure to the receiving Party, as evidenced by the prior written records of the receiving Party;
or

 

(b) either before
or after the date of the disclosure to the receiving Party is lawfully disclosed to the receiving Party by sources other than
the disclosing Party rightfully in possession of the Confidential Information; or

 

(c) either before
or after the date of the disclosure to the receiving Party becomes published or generally known to the public, other than through
the sale of Licensed Products in the ordinary course. through no fault or omission on the part of the receiving Party or an affiliated
party; or

 

(d) is independently
developed by or for the receiving Party without reference to or reliance upon the Confidential Information; or

 

(e) is required to
be disclosed by the receiving Party to comply with applicable laws, to defend or prosecute litigation or to comply with governmental
regulations, provided that the receiving Party provides prior written notice of such disclosure to the other party and takes reasonable
and lawful actions to avoid and/or minimize the degree of such disclosure.

 

VII. Termination

 

Vll.1. Term. This Agreement shall remain
in effect until terminated in accordance with the provisions of this Article VII.

 

     

     

    

 

VIL2. Termination for Breach. Licensee
shall be entitled to terminate this Agreement by written notice to Licensor in the event that Licensor shall be in default of
any of its obligations hereunder and shall fail to remedy any such default within 60 days after notice thereof by Licensee. Licensor
shall be entitled to terminate this Agreement by written notice to Licensee in the event that Licensee shall be in default of
any of its obligations hereunder and shall fail to remedy any such default within sixty (60) days after notice thereof by Licensor.
Upon termination of this Agreement pursuant to this Section 7.2, no Party shall be relieved of any obligations incurred prior
to such termination. of any Licensed Products, claimed by reason of breach of warranty, negligence. product defect. or other similar
cause of action, regardless of the form ln which any such claim is made. The Party distributing the Licensed Products under this
Agreement (the "Distributing Party" or "Indemnifying Party") shall defend the other Party (the "Indemnified
Party") at the Distributing Party's cost and expense, and will indemnify and hold harmless the Indemnified Party, from and
against any and all claims. losses. costs, damages, fees, or expenses arising out of or in connection with the commercialization,
marketing or sale of the Licensed Products (other than claims based on infringement or misappropriation), including, but not limited
to, any actual or alleged injury, damage, death, or other consequence occurring to any legal or natural person or property, as
a result, directly or indirectly, of the possession, use or consumption of any Licensed Products, claimed by reason of breach
of warranty, negligence. product defect or other similar cause of action. regardless of the form in which any such claim is made.
In the event of any such claim against an Indemnified Party, such Indemnified Party shall promptly notify the Indemnifying Party
in writing of the claim and the Indemnifying Party shall manage and control, at its sole expense, the defense of the claim and
its settlement. The Indemnified Party shall cooperate with the Indemnifying Party and may, at its option and expense, be represented
in any such action or proceeding. The Indemnifying Party shall not be liable for any litigation costs or expenses incurred by
the Indemnified Party without the Indemnifying Party's written authorization.

 

Vll1.2. Reports and Payments. Licensee
shall deliver to Licensor within 60 days after the end of each calendar quarter a written report showing its computation of royalties
and sublicense fees due under this Agreement for such calendar quarter. Simultaneously with the delivery of each such report,
Licensee shall tender payment of all amounts shown to be due thereon. The royalty payments and sublicense fees due on sales in
currencies other than U.S. dollars shall be calculated using the appropriate exchange rate for such currency quoted by the Citibank
foreign exchange desk on the close of business on the business day immediately preceding the date of such report. All amounts
due under this Agreement shall be paid to Licensor in United States dollars (U.S. $) by wire transfer to an account in a United
States bank designated by Licensor. or in such other form and/or manner as Licensor may reasonably request. During the term of
this Agreement, Licensor shall have the right from time to time {not to exceed once during each calendar year) to have an independent
certified public accountant inspect, during normal business

 

     

     

    

 

[insert address. tel, fax and email}

 

		If to Licensor:	Blue
                                         Ivory Holdings Ltd.

 

[insert address, tel. fax and emaiiJ

 

Vlll.6. No Agency. Nothing herein shall
be deemed to constitute Licensee, on the one hand, or Licensor, on the other hand. as the agent or representative of the other,
or as joint venturers or partners for any purpose. Neither Licensee, on the one hand, nor Licensor, on the other hand, shall be
responsible for the acts or omissions of the other. No Party will have authority to speak for. represent or obligate the other
Party in any way without prior written authority from such other Party.

 

Vlll.7. Entire Agreement. This Agreement
and the Schedules hereto (which Schedules are deemed to be a part of this Agreement for ail purposes) contain the full understanding
of the Parties with respect to the subject matter hereof and supersede all prior understandings and writings relating thereto.
No waiver, alteration or modification of any of the provisions hereof shall be binding unless made in writing and signed by the
Parties.

 

Vlll.8. Headings. The headings contained
in this Agreement are for convenience of reference only and shall not be considered in construing this Agreement.

 

Vll1.9. Severability. In the event that
any provision of this Agreement is held by a court of competent jurisdiction to be unenforceable because it is invalid or in conflict
with any law of any relevant jurisdiction, the validity of the remaining provisions shall not be affected.

 

Vlll.10. Assignment. No Party to this
Agreement may assign its rights or obligations hereunder without the prior written consent of each other Party; provided, however,
that each Party may

 

     

     

    

 

	BLUE IVORY HOLDINGS LTD.	 	AXXESS PHARMA INC.
	 	 	 
	By:	/s/ Alan Cole
    	 	By:	/s/ Daniel P. Bagi
	 	Alan Cole President	 	 	Daniel P. Bagi, President

 

     

     

    

 

Schedule A

 

Drug ldenitification Numbers

 

     

     

    

 

Schedule 8

 

Patents and Patent Applications

 

     

     

    

 

ADDENDUM

 

This Addendum (the
"Addendum"), dated as of October 1, 2012, by and between AXXESS PHARMA, INC., a Nevada corporation, (the "Company"),
and Blue Ivory Holdings International Ltd, (BIH) a Nassau, Bahamas, Corporation

 

WHEREAS:

 

A.        The
Company and the Licensor are party to a Pharmaceutical License Agreement dated as of October I, 2012 (the "Agreement"),
pursuant to which, among other things, BIH has the right to quarterly payments of $125,000, totalling $5,000,000 over a period
often years and such amount is owed to BIH by the Company; and

 

B.         Pursuant
to the Agreement the Company agrees to issue 25,000,000 common shares and 20,000,000 preferred shares on a collateral basis until
license has been paid in full to BIH.

 

C.         Pursuant
to the License Agreement, in the event of default BIH shall have the right to sell1% of their 25,000,000 shares quarterly as of
January 1, 2014.

 

NOW, THEREFORE, in
consideration of the promises and the mutual covenants contained herein and other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the Company and the Investor hereby to amend the Note as follows:

 

		1.	This Agreement, the rights of the
                                         parties under and in connection herewith, and all actions arising in whole or part under
                                         or in connection herewith will be governed by and construed in accordance with the laws
                                         of the State of Nevada. The parties hereby irrevocably and unconditionally submit to
                                         the jurisdiction of any federal or state court located within the State of Nevada over
                                         any dispute for purposes of any action, suit or proceeding arising out of or relating
                                         to this Agreement. Each party irrevocably waives any objection it may have to the venue
                                         of any action, suit or proceeding brought in such court or to the convenience of the
                                         forum. No modification or waiver of any provision hereof shall be enforceable unless
                                         approved by the Investor in writing. No failure or delay in the exercise of any power,
                                         right or privilege hereunder shall operate as a waiver thereof, nor shall any single
                                         or partial exercise of any such power, right or privilege preclude other or further exercise
                                         thereof or of any other right, power or privilege. This Agreement may be executed in
                                         one or more counterparts, and by the different parties hereto in separate counterparts,
                                         each of which when executed shall be deemed to be an original but all of which taken
                                         together shall constitute one and the same agreement. Each party shall do and perform,
                                         or cause to be done and performed, all such further acts and things, and shall execute
                                         and deliver all such other agreements, certificates, instruments and documents, as the
                                         other party may reasonably request in order to carry out the intent and accomplish the
                                         purposes of this Agreement.

 

     

     

    

 

		2.	Any notice, demand, request, waiver
                                         or other communication required or permitted to be given hereunder shall be in writing
                                         and shall be effective (a) upon hand delivery or facsimile (with facsimile machine confirmation
                                         of delivery received) at the address or number designated below (if delivered on a business
                                         day during normal business hours where such notice is to be received), or the first business
                                         day following such delivery (if delivered other than on a business day during normal
                                         business hours where such notice is to be received) or (b) on the second business day
                                         following the date of mailing by express courier service, fully prepaid, addressed to
                                         such address, or upon actual receipt of such mailing, whichever shall first occur. The
                                         address for such communications shall be:

 

If to the Company:

 

Axxess Pharma, Inc.

 

If to the Licensor:

 

Blue Ivory Holdings International, Ltd.

 

Either party hereto may from time to time change
its address for notices by giving at least 10 days advance written notice of such changed address to the other party hereto.

 

[Signature Page Follows]

 

     

     

    

 

IN
WITNESS WHEREOF, the Investor and the Company have caused this Agreement to be duly executed as
of the date first written above.

 

	 	THE COMPANY:
	 	 
	 	AXXESS PHARMA, INC
	 	 
	 	By:	/s/ Daniel Bagi, M.D.
	 	Name:   Daniel Bagi, M.D.
	 	Title:     President
	 	 
	 	LICENSOR:
	 	 
	 	Blue Ivory Holdings International Ltd.
	 	 
	 	By:	/s/ Alan Cole
	 	Name:  Alan Cole
	 	Title:    President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00250-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00250-of-00352.parquet"}]]